Payment overview · 2025
General Payments
$731.35
32 reported records · 21 companies
Healthcare provider profile · identity verified
Timothy John Doyle, DO
Allopathic & Osteopathic Physicians|Family Medicine · TOMBALL, TX · NPI 1073540381
Verified facts
What the public records show
CMS Open Payments records show Timothy John Doyle, DO received $731.35 in general payments during 2025 across 32 reported records.
Echosens North America, Inc. accounted for 12.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $89.43 | 12.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $80.76 | 11.0% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $74.53 | 10.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $62.61 | 8.6% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $61.15 | 8.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $42.56 | 5.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.69 | 5.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.26 | 4.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $26.20 | 3.6% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $24.47 | 3.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.49 | 3.1% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $22.39 | 3.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.09 | 2.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.76 | 2.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.06 | 2.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.10 | 2.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.08 | 2.2% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.78 | 2.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.86 | 2.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$13.60 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.48 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $731.35 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $89.43 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $62.61 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $61.15 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.42 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $42.56 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.69 | 2 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $33.34 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 500 | 167 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 361 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 313 | 112 |
| Lisinopril | Lisinopril | 301 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 96 |
| Losartan Potassium | Losartan Potassium | 226 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 203 | 87 |
| Furosemide | Furosemide | 176 | 65 |
| Metformin Hcl | Metformin Hcl | 171 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 51 |
| Metformin Hcl Er | Metformin Hcl | 113 | 44 |
| Omeprazole | Omeprazole | 109 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 36 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 106 | 74 |
| Carvedilol | Carvedilol | 92 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 32 |
| Prednisone | Prednisone | 89 | 51 |
| Montelukast Sodium | Montelukast Sodium | 86 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 85 | 31 |
| Gabapentin | Gabapentin | 84 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 21 |
| Allopurinol | Allopurinol | 75 | 23 |
| Trazodone Hcl | Trazodone Hcl | 72 | 29 |
| Farxiga | Dapagliflozin Propanediol | 69 | 23 |
| Potassium Chloride | Potassium Chloride | 61 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 21 |
| Finasteride | Finasteride | 60 | 27 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 60 | 17 |
| Meloxicam | Meloxicam | 59 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 21 |
| Ezetimibe | Ezetimibe | 57 | 28 |
| Azithromycin | Azithromycin | 56 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 14 |
| Glipizide Er | Glipizide | 49 | 16 |
| Eliquis | Apixaban | 48 | 14 |
| Famotidine | Famotidine | 48 | 22 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | 23 |
| Tramadol Hcl | Tramadol Hcl | 46 | 17 |
| Fenofibrate | Fenofibrate | 45 | 16 |
| Sertraline Hcl | Sertraline Hcl | 44 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 17 |
| Spironolactone | Spironolactone | 40 | 11 |
| Methylprednisolone | Methylprednisolone | 39 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | 12 |
| Jardiance | Empagliflozin | 37 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 20 |
| Simvastatin | Simvastatin | 33 | 15 |
| Glimepiride | Glimepiride | 32 | 12 |
| Memantine Hcl | Memantine Hcl | 31 | 12 |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 23 |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 15 |
| Mupirocin | Mupirocin | 25 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 25 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 13 |
| Temazepam | Temazepam | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Prolia | Denosumab | 16 | 11 |
| Unithroid | Levothyroxine Sodium | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 11 |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 12 |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | 11 |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $731.35 · 32 records | Echosens North America, Inc. | AIRSUPRA, CONTRAVE, Cologuard Collection Kit, FREESTYLE LIBRE 3, Fibroscan, GEMTESA, Heplisav-B, INSPIRE, JOT DX, Korlym, Leqembi, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SAPIEN 3 Ultra RESILIA, The Cologuard Plus Collection Kit, VENASEAL, VRAYLAR, Veozah, XIFAXAN, YUPELRI, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error